In order to combat the resistance of CD19-negative cells, CD19/CD20 CAR-T cells have been used in a clinical trial (NCT04007029) to treat patients with recurrent or refractory B-cell lymphoma. This evidence concerns the gene CD19 and B-cell non-Hodgkin lymphoma.